Welcome to our dedicated page for Rain Enhancement news (Ticker: RAIN), a resource for investors and traders seeking the latest updates and insights on Rain Enhancement stock.
Rain Enhancement Technologies Holdco, Inc. (NASDAQ: RAIN) is a Nasdaq-listed company focused on ionization-based weather modification technology, including rainfall generation, snow enhancement, and fog mitigation. The RAIN news feed on Stock Titan aggregates company announcements, scientific updates, and regulatory disclosures that explain how its Weather Enhancement Technology Array (WETA) platform is being tested, deployed, and evaluated.
Investors and observers following RAIN news can expect coverage of technology trials and field results, such as reports on precipitation enhancement in international locations and early indications from U.S. installations. The company’s releases discuss peer-reviewed findings that its ionization rainfall generation systems have produced statistically significant rainfall increases in randomized trials, and they provide narrative detail on how installations are designed to influence rainfall and snowpack in water-stressed regions.
RAIN news also highlights corporate and governance developments, including appointments to the board of directors and the addition of strategic and technical advisors with backgrounds in weather modification, atmospheric science, quantum physics, and corporate governance. These items provide context on how the company is building scientific and leadership capacity as it pursues commercialization of its WETA platform.
Regulatory and listing-related updates form another important category of RAIN news. The company has issued press releases and filed Form 8-K reports describing its interactions with The Nasdaq Stock Market LLC, including prior notices about continued listing standards and subsequent confirmation that its securities are listed on the Nasdaq Capital Market under the symbols RAIN and RAINW. By reviewing this news stream, readers can track both operational progress in weather enhancement projects and key corporate milestones.
Rain Therapeutics Inc. has announced a clinical supply agreement with Roche to evaluate the combination of milademetan, an MDM2 inhibitor, with atezolizumab, a PD-L1 antibody, targeting genetically selected cancer patients. This agreement includes plans for a Phase 1 trial assessing safety and efficacy in patients with specific tumors, with a launch expected in the second half of 2022. Rain is also advancing milademetan's use in other ongoing trials for various cancers and has received FDA Orphan Drug Designation for liposarcoma.
Rain Therapeutics Inc. (NasdaqGS: RAIN) announced that CEO Avanish Vellanki will present at two upcoming virtual conferences: the JP Morgan Chase 40th Annual Healthcare Conference on January 13, 2022, and the H.C. Wainwright Bioconnect Conference starting January 10, 2022. The JP Morgan presentation will be live at 11:15 a.m. ET, while H.C. Wainwright will feature a prerecorded session available from 7:00 a.m. ET. Both events highlight Rain's focus on precision oncology, targeting therapies for genetically selected patients.
Rain Therapeutics Inc. (NASDAQ: RAIN) announced its inclusion in the NASDAQ Biotechnology Index (NBI), effective December 20, 2021. This index tracks NASDAQ-listed companies in the biotechnology and pharmaceuticals sector. To qualify, companies must have a market cap of at least $200 million and an average daily trading volume of 100,000 shares. Rain Therapeutics focuses on developing precision oncology therapies, including its lead candidate, milademetan, an oral MDM2 inhibitor targeting various cancers. This index inclusion may enhance visibility and investment interest in Rain.
Rain Therapeutics Inc. (NasdaqGS: RAIN) announced that its CEO, Avanish Vellanki, will partake in two upcoming virtual conferences: the Piper Sandler 33rd Annual Healthcare Conference from November 29 to December 2, 2021, and the Evercore ISI 4th Annual Health CONx Virtual Conference on December 2, 2021. The Piper Sandler presentation will be available starting November 22, 2021, at 10:00 a.m. ET. Both events will include webcasts accessible through Rain's website, with replays available for 30 days post-presentation. Rain focuses on precision oncology, developing targeted therapies for cancer.
Rain Therapeutics has initiated the Phase 2 MANTRA-2 trial to assess the safety and efficacy of milademetan, an MDM2 inhibitor, in patients with MDM2-amplified advanced solid tumors. The trial aims to enroll approximately 65 patients refractory to standard therapies, focusing on wild-type p53 tumors. The primary endpoint is the objective response rate. Interim results are expected in late 2022. Milademetan has shown promise in earlier trials, including a Phase 1 study demonstrating anti-tumor activity in liposarcoma and other solid tumors.
Rain Therapeutics reported a net loss of $18.4 million for Q3 2021 and $33.4 million for the first nine months, compared to losses of $10.4 million and $15.6 million in the same periods of 2020. The company ended Q3 with $150.1 million in cash, providing a runway to advance clinical trials, including the MANTRA-3 trial for milademetan in Merkel cell carcinoma, set to start in mid-2022. R&D expenses rose to $15.3 million for Q3 2021, up from $7.9 million in Q3 2020. Milademetan shows promise in ongoing and upcoming trials, aiming for significant oncology advancements.
Rain Therapeutics (NASDAQ: RAIN) has announced the initiation of the MANTRA-3 Phase 2 clinical trial for milademetan as a treatment for Merkel cell carcinoma (MCC) in patients who are resistant to immunotherapy. The trial, set to start mid-2022, will enroll approximately 30 patients. The primary objective is to assess the objective response rate through RECIST criteria. This move comes after promising preclinical results and replaces a previously planned trial for intimal sarcoma. Rain will also host its first annual R&D Day webinar today to discuss relevant oncology research.
Rain Therapeutics Inc. (NasdaqGS: RAIN) is set to report its Q3 financial results for the period ending September 30, 2021, on November 10, 2021. The company will also highlight recent advancements in precision oncology therapeutics during a conference call at 1:30 p.m. PT (4:30 p.m. ET). Rain focuses on developing therapies targeting oncogenic drivers through a tumor-agnostic strategy, with its lead candidate milademetan (RAIN-32) being an oral MDM2 inhibitor. Investors can access a recorded version of the call on the company’s website for 30 days.
Rain Therapeutics Inc. (NasdaqGS: RAIN) will host a virtual Research and Development (R&D) day on November 9, 2021, featuring prominent oncology experts discussing milademetan, a precision oncology therapy targeting MDM2-mediated p53 loss. CEO Avanish Vellanki expressed excitement to share updates on the drug's potential in various cancer populations. Key opinion leaders will present findings related to ER+ breast cancer, Merkel cell carcinoma, and liposarcoma, among others. The event will also include management insights and Q&A sessions.
Rain Therapeutics presented promising data on its MDM2 inhibitor, milademetan, at the 2021 AACR-NCI-EORTC conference. The findings suggest significant anti-tumor activity in genetically selected models including advanced cancers with MDM2 amplification, and GATA3 mutant ER-positive breast cancer. Notably, milademetan showed the potential to treat Merkel cell carcinoma and ER+ breast cancer that are resistant to current therapies. The company is ongoing with Phase 3 trials for liposarcoma and plans a Phase 2 tumor-agnostic trial.